Labcorp Drug Development GMP Pharmacy Study

A mid-sized drug manufacturer was in Phase I clinical trials for a molecule designed to treat adenoviral infection. Their contract manufacturing organization (CMO) predicted a delay in drug production leading to a three- to six-month delay in study start-up. The client inquired if Labcorp could manufacture the drug on time and manage the clinical trial with their supplied active pharmaceutical ingredient (API). This sponsor needed fast turnaround to get the study on track and on budget, with cGMP quality plus flexibility to adjust the formulation if needed.